Clinical Trial Search

Primary: Number of Participants Who Achieve a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI) Score — 111; 111 Participants

Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001

Primary: Clinical Success — 18; 3 participants — p=0.0003

Primary: Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12 — 5; 0…

Primary: Percentage of Participants Achieving a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 24 — 78.2; 59.9 Percentage of participants…

Primary: The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85…

Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 Response at Week 24 — 89.52; 33.68 Percentage of participants — p=<.0001

Primary: Number of Patients With Physician's Global Assessment (sPGA) Score 0 or 1 — 24 Participants

Primary: Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1 — 25; 44; 41; 45 Participants — p=<0.0001

Primary: Psoriasis Severity — 4.25 units on a scale

Primary: Percentage of Participants Who Achieved Psoriasis Area and Severity Index 75 (PASI 75) at Week 16 — 89.7; 91.6 Percentage of Participants

Primary: Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 — 5.8; 18.0; 44.2…

Primary: Percentage of Subjects Who Have 75% or More Reduction in [Psoriasis Area-and-severity Index Score (PASI)] (PASI75) — 8; 0 Participants

Primary: Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36 — 4; 2 participants

Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at…

Primary: Psoriasis Area and Severity Index (PASI) 75 Response Rate at Week 10 — 71 Percentage of participants

Primary: Safety - Treatment Emergent Adverse Events (TEAEs) - Number of TEAEs — 27; 32; 0; 0 TEAEs

Primary: Proportion of Patients Achieving Psoriasis Area and Severity Index (PASI) 75 (i.e. 75% Reduction From Baseline PASI Score). (Scores Range From 0 (Minimum) to 30…

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 13; 7; 20; 11 Participants

Primary: Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline — 13.7…

Primary: Mean Epidermal Thickness at End-of-Treatment (EOT) Compared to Pre-treatment — -8.8; -48.5; 17.3 Millimeters

Primary: Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16 — 9.3; 37.2; 58.1…

Primary: Percentage of Subjects Achieving a Minimum 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI-75) at End-of-treatment (EOT) — 11.8; 22.0; 7.8 %…

Primary: Achievement of Psoriasis Activity and Severity Index (PASI75) Response at Week 12 — 6.8; 74.6; 82.8 percentage of subjects — p=<0.001

Primary: Percentage of Participants Achieving Greater Than or Equal to (>=) 75% Reduction From Baseline in Psoriasis Area Severity Index (PASI) Score (PASI-75) at Week 16 — 58.3…

Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants

Primary: Severity of Psoriasis — 2.68; 1.84 units on a scale

Primary: Percentage of Participants (Who Achieved a Partial Response Defined as ≥ 50% But < 75% Improvement in Psoriasis Area and Severity Index (PASI) After 12 Weeks of…

Primary: Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16. — 0.78; 0.42 Proportion of participants — p=<0.001

Primary: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response Up to Week 16 - Investigational Treatment Period — 0; 0; 0; 0 Percentage of…